Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. filed a current report describing a new press release that shares preliminary fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and the company’s cash and cash equivalents as of December 31, 2025. These figures are early management estimates and may change after Invivyd completes its financial closing procedures and finalizes its audited financial statements for the quarter and full year 2025.
The company explains that the preliminary data have not been audited by its independent registered public accounting firm and that additional information will be needed for a full picture of its financial position and results of operations. Invivyd also filed the full press release as an exhibit and made an updated corporate presentation available on its website, providing investors with recent business highlights alongside the early financial indicators.
Invivyd, Inc. reported that it has issued a press release announcing the selection of RSV antibody candidate VBY329, which it describes as a potential best-in-class therapy. The company stated in the release title that it is targeting investigational new drug (IND) readiness for this candidate in the second half of 2026, signaling a planned next step toward clinical development. This update was furnished as an informational 8-K under Other Events, along with the full press release as an exhibit.
Invivyd, Inc. director reports purchase of common stock
A director of Invivyd, Inc. (IVVD) reported buying 50,000 shares of common stock on 11/19/2025. The Form 4 shows a transaction code "P" for a purchase at a price of $2.50 per share. After this transaction, the reporting person beneficially owns 50,000 shares, held directly. An accompanying note explains that these shares were acquired in an underwritten public offering of Invivyd common stock.
Invivyd, Inc. entered into an underwriting agreement for an underwritten public offering of 44,000,000 shares of common stock and pre-funded warrants to purchase 6,000,000 shares. The shares were priced at $2.50 each and the pre-funded warrants at $2.4999, with an option for underwriters to buy up to an additional 7,500,000 shares at the same price. The company reports net proceeds of approximately $117.2 million after fees, and the offering closed on November 19, 2025.
Invivyd plans to use the proceeds, together with existing cash, to prepare commercially for the potential launch of VYD2311, continue research and development for programs such as RSV and measles, advance its SPEAR Study Group work on Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes. The pre-funded warrants are exercisable immediately, have no expiration, allow cash or cashless exercise, and include beneficial ownership limits generally starting at 4.99% or 9.99%, adjustable up to 19.99% with at least 61 days’ prior notice.
Invivyd, Inc. is conducting a primary offering of 44,000,000 shares of common stock and pre-funded warrants to purchase up to 6,000,000 shares at a public offering price of $2.50 per share and $2.4999 per pre-funded warrant, for gross proceeds of $124,999,400. After underwriting discounts and estimated expenses, Invivyd expects net proceeds of about $117.2 million, or $134.8 million if underwriters fully exercise their option to buy an additional 7,500,000 shares. The company plans to use the cash to prepare for the potential launch of its COVID-19 antibody VYD2311, advance pipeline programs such as RSV and measles, support Long COVID research via the SPEAR Study Group, and for working capital and general corporate purposes. The transaction will dilute existing holders, with pro forma net tangible book value rising from $0.52 to about $0.84 per share, implying $1.66 per-share dilution to new investors paying the offering price.
Invivyd, Inc. is conducting an underwritten public offering of its common stock on the Nasdaq Global Market under an effective shelf registration statement. This primary equity raise is expected to provide additional capital for the company’s COVID-19 antibody franchise and broader pipeline.
Invivyd is a biopharmaceutical company focused on monoclonal antibodies that protect against serious viral diseases, starting with SARS‑CoV‑2. Its first authorized product, PEMGARDA (pemivibart), has U.S. emergency use authorization for pre‑exposure COVID‑19 prevention in certain immunocompromised patients. The company is also advancing VYD2311 through its REVOLUTION clinical program, including planned Phase 3 trials, and plans to use offering proceeds alongside existing cash to support potential commercialization of VYD2311, additional R&D such as RSV and measles programs, Long COVID research via the SPEAR Study Group, and general corporate purposes.
Invivyd, Inc. reported Q3 2025 results showing higher revenue and sharply lower operating expenses, alongside a going concern warning. Product revenue reached $13.1 million, up from $9.3 million a year ago. The net loss narrowed to $10.5 million from $60.7 million, driven by a large decline in research and development expense ($8.0 million vs. $57.9 million). Cash and cash equivalents were $84.97 million, up from $69.35 million at year-end.
The company strengthened liquidity through equity financings, including an underwritten public offering and at‑the‑market sales, bringing in $58.45 million of net cash in the nine months ended September 30, 2025. Stockholders’ equity improved to $93.07 million from $67.54 million. Management disclosed “substantial doubt” about the ability to continue as a going concern without additional funding.
Operationally, PEMGARDA remains authorized under EUA. The FDA cleared the IND for VYD2311 in October 2025, with Phase 3 trials (DECLARATION and LIBERTY) expected to begin around year‑end 2025 and top‑line data anticipated mid‑2026. As of October 30, 2025, shares outstanding were 233,122,834.
Invivyd, Inc. (IVVD) filed an 8-K reporting Q3 2025 updates. The company furnished a press release announcing financial results for the quarter ended September 30, 2025 as Exhibit 99.1 under Item 2.02. This information is furnished and not deemed filed under Section 18 of the Exchange Act.
Invivyd also posted an updated corporate presentation on November 6, 2025, filed as Exhibit 99.2 and available on its website. The filing lists these materials and related exhibit identifiers.
Invivyd (IVVD) filed a routine update. On October 30, 2025, the company posted an investor presentation on its website and filed it as Exhibit 99.1 to a Form 8‑K under Item 8.01. The filing indicates the presentation is available at www.invivyd.com and is incorporated by reference in the report.
Invivyd, Inc. filed a current report to highlight a key regulatory milestone for its COVID-19 program. On October 6, 2025, the company issued a press release announcing U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311, described as a vaccine-alternative antibody to prevent COVID. The press release was furnished as Exhibit 99.1 to this report.